1. Scrip
  2. >>Business
  3. >>Manufacturing

Lilly Commits Another $5.3bn To Tirzepatide Supply Expansion Effort

 
• By Joseph Haas

Lilly is now spending about $9bn total to bring an Indiana manufacturing site for tirzepatide to readiness, although it is not expected to supply finished product until 2026.

Manufacturing
Lilly is increasing manufacturing spending driven by tirzepatide demand • Source: Shutterstock

Eli Lilly and Company is committing an additional $5.3bn to its ongoing efforts to ramp up manufacturing of tirzepatide, the blockbuster dual GLP-1/GIP agonist approved as Mounjaro for type 2 diabetes and Zepbound for obesity, at an in-development site in Indiana slated to produce its first doses in 2026 and continue scaling up production capacity into 2028. The multibillion-dollar expansion comes as the company and its competitor Novo Nordisk A/S continue to struggle to keep up with demand for weight loss-inducing medicines that far outstrips existing capacity to manufacture the products.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

US Tariffs And Manufacturing Concentration: Double-Edged Sword?

 
• By Anju Ghangurde

India and the US are the major manufacturers of finished dosages for the US market in terms of volume (China accounts for 9% of injectables), though the US relies heavily on India for solid oral dosage forms and specific generics, including lenalidomide and albuterol. Scrip talks to experts on some of the key implications of geographic concentration of production for the US market amid the specter of tariffs.

Novartis $23bn US Investment Is Music To Trump’s Ears

 
• By Kevin Grogan

The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

 
• By Dexter Jie Yan

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

Trump’s Tariff Rollercoaster Keeps Pharma On Edge

 
• By Jessica Merrill

The rollout of Trump’s tariff plan has been a policy whiplash, but despite a 90-day pause on tariffs, it appears the US president is still holding a grudge with industry over drug pricing.

More from Business

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s tariff rollercoaster; regulatory, economic uncertainties hang over Q1 earnings; IPOs rise in Q1 but may slow; Chinese deal-making matures; and AstraZeneca talks about Chinese innovation.

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By Joseph Haas

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.